cefetamet and Respiratory-Tract-Infections

cefetamet has been researched along with Respiratory-Tract-Infections* in 4 studies

Other Studies

4 other study(ies) available for cefetamet and Respiratory-Tract-Infections

ArticleYear
[Antimicrobial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections. Part III].
    The Japanese journal of antibiotics, 1999, Volume: 52, Issue:6

    Antimicrobial activities of cefetamet (CEMT) against clinically isolated strains from patients with community acquired respiratory tract infections were investigated in comparison with those of other oral beta-lactam antibiotics during the period from January to March, 1998. The results are summarized as follows; 1. CEMT showed strong antimicrobial activities against three major pathogens causing community acquired respiratory tract infections, Streptococcus pyogenes, Streptococcus pneumoniae and Haemophilus influenzae. However, antimicrobial activities of CEMT against penicillins (PCs)-intermediate S. pneumoniae (PISP) and PCs-resistant S. pneumoniae (PRSP) were slightly weaker than those of some of the reference antibiotics. 2. No chronological changes of CEMT-MIC level were observed in the antimicrobial activities against S. pyogenes, H. influenzae, Moraxella subgenus Branhamella catarrhalis or Klebsiella pneumoniae subsp. pneumoniae. In contrast to this, due to the increase of PISP and PRSP strains, resistance to CEMT appears increasing with time.

    Topics: Anti-Bacterial Agents; Ceftizoxime; Cephalosporins; Community-Acquired Infections; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Penicillin Resistance; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes

1999
[Antibacterial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections (II)].
    The Japanese journal of antibiotics, 1994, Volume: 47, Issue:12

    Antibacterial activities of cefetamet (CEMT) against clinically isolated strains from patients with community acquired respiratory tract infections were compared to those of other oral beta-lactam antibiotics in the period from January to March 1994. The following results were obtained. 1. CEMT showed strong antibacterial activities against three major pathogens causing community acquired respiratory tract infections, Streptococcus pyogenes, Streptococcus pneumoniae, and Haemophilus influenzae. However, antibacterial activities of CEMT against benzylpenicillin (PCG)-insensitive S. pneumoniae (PISP) and PCG-resistant S. pneumoniae (PRSP) were slightly weaker than of those of some the reference antibiotics. 2. No MIC value changes of CEMT were observed from year to year against Moraxella subgenus Branhamella catarrhalis and Klebsiella pneumoniae.

    Topics: Bacteria; Ceftizoxime; Community-Acquired Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes

1994
[Antimicrobial activity of cefetamet against clinically isolated microbial strains collected from urban RTI patients].
    The Japanese journal of antibiotics, 1992, Volume: 45, Issue:11

    The authors studied antimicrobial activities of cefetamet (CFMT) and other leading oral antimicrobials of beta-lactam class against clinically isolated strains from urban respiratory tract infection (RTI) patients from January to March, 1992. 1. CFMT showed potent antimicrobial activities against "3 primary pathogens" of RTIs i.e., Streptococcus pyogenes, Streptococcus pneumoniae, and Haemophilus influenzae, but the drug had a slightly higher MIC than those of a few oxime-type cephems already on the market. 2. CFMT was as stable as cefixime to beta-lactamase, generated by Moraxella subgenus Branhamella catarrhalis, which reduces the antimicrobial activity of cephems. 3. Blood concentrations of CFMT after administering cefetamet pivoxil (CFMT-PI), an oral form of the drug, exceeded the MIC80 against the "3 primary pathogens" as well as M. (B) catarrhalis and Klebsiella pneumoniae, for a duration of approximately 9 and 11 hours, respectively, after single doses of 250 and 500 mg. This suggests that CFMT could remain above the MICs for a sufficient time period with twice daily dosages of normal dose levels. 4. It is concluded that CFMT-PI will be useful for treating urban RTIs.

    Topics: Anti-Bacterial Agents; Bacteria; Ceftizoxime; Humans; Microbial Sensitivity Tests; Respiratory Tract Infections

1992
[Antimicrobial activity of cefetamet against fresh clinical isolates of Branhamella catarrhalis].
    The Japanese journal of antibiotics, 1992, Volume: 45, Issue:4

    Against strains of Branhamella catarrhalis which were separated from various RTIs (respiratory tract infections) in 1991 antimicrobial activities (MICs) of cefetamet (CFMT) were determined, and the following conclusions were obtained. 1. The MIC80 of CFMT against B. catarrhalis was 0.39 microgram/ml, which was higher than that of cefixime (CFIX) by one dilution or twofold, but was lower than that of cefpodoxime (CPDX) by two dilutions or fourfold and that of cefotiam (CTM) by three dilutions or eightfold. 2. The fact that all of the 50 strains tested were beta-lactamase producers appeared to indicate that CFMT was stable against BRO-1 and BRO-2 beta-lactamases produced by B. catarrhalis. 3. Blood concentrations of the test drug, CFMT, and control drugs upon normal single doses were calculated using pharmacokinetic parameters. Lengths of time periods during which drug concentrations stayed above their MICs against B. catarrhalis obtained in this study were determined for CFMT, CFIX, CPDX and CTM. They were, respectively, 12 hours, 12 hours, 6 hours, and 2 hours, thus CFMT appeared to remain above MIC for sufficiently long time for the treatment of RTIs which are affected by B. catarrhalis directly or indirectly.

    Topics: beta-Lactamases; Cefixime; Cefotaxime; Cefotiam; Cefpodoxime; Ceftizoxime; Drug Resistance, Microbial; Drug Stability; Humans; Moraxella catarrhalis; Respiratory Tract Infections

1992